Discount Bank to sell Harel pensions

Discount will sell the funds through its pension consulting subsidiary, Logos Pensionary Models and Wage Benefits Ltd.

By DANIEL KENNEMER
February 20, 2006 07:38
discount bank88

discount bank88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israel Discount Bank agreed with Harel Insurance Investments Ltd. on Sunday to sell the group's Adi pension fund, calling it "another important step in [its] preparations to provide financial consulting." Discount will sell the funds through its pension consulting subsidiary, Logos Pensionary Models and Wage Benefits Ltd. The Bachar reform, signed into law last summer, requires banks to sell their holdings in provident and mutual funds, and allows them, instead, to sell to their clients funds owned and managed by other companies. Banks would then charge the companies a distribution fee.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS